Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8601-8610 Newer>

Pharmaceutical Executive March 1, 2013 Keeling & Paz	Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics.
Pharmaceutical Executive March 1, 2013 Al Topin	Less Selling, More Time What can happen when pharmaceutical reps focus on the physician-patient conversation?
Pharmaceutical Executive March 1, 2013	Who's Really in Charge of European Drug Registration? The European Commission blocks the authorization of a life-saving liver drug outside of France.
Pharmaceutical Executive March 1, 2013 Bonifant & Setrakianis	Test and Learn: Making Confident Decisions on the Commercial Side Companies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual.
Pharmaceutical Executive March 1, 2013 Forcellina & Akannac	Embedding Market Access in Today's Pharma Business Model A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.
Pharmaceutical Executive March 1, 2013 Henninger & Feldstein	Safeguarding the Value of Patent Assets As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property.
Pharmaceutical Executive March 1, 2013	Country Report: China China's pharmaceutical industry is making record gains. Four years ago, China was the world's fifth largest market. Now, it has bypassed France and Germany to become the third largest.
Chemistry World March 21, 2013 Phillip Broadwith	AstraZeneca partners with Moderna for $240 million Moderna has developed a way to use messenger RNA (mRNA), the molecule cells use to turn DNA into proteins, to stimulate the production of specific proteins in cells where disease has diminished or eliminated their ability to do so.
Chemistry World March 21, 2013 Andy Extance	Court convicts ex-Aptuit researcher over drug data Steven Eaton, a former employee at drug discovery and development firm Aptuit's Riccarton site in Scotland, produced flawed data over six years.
Chemistry World March 19, 2013 Simon Hadlington	Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016.
<Older 8601-8610 Newer> Return to current articles.